Drug Trial Radar · NCT07729462
A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Aug 26, 2026
Primary completion
Oct 21, 2028
Study completion Jan 19, 2029
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jul 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine attacks in adults and for the preventive treatment of episodic migraine in adults when administered every other day. This study evaluates once daily rimegepant for the preventive treatment of chronic migraine. After a 28-day observation period without study intervention, eligible participants will be randomized in a 1:1 ratio to receive either rimegepant 75 mg orally disintegrating tablet (ODT) or matching placebo once daily for 12 weeks under double-blind conditions. Participants who remain eligible at the end of the double-blind treatment phase will enter a 12-week open-label treatment period, during which all participants will receive open-label rimegepant 75 mg once daily. During this period, participants may also take an additional rimegepant tablet for the acute treatment of breakthrough migraine attacks, up to 10 doses per month. A 28-day follow-up period completes the approximately 32-week study. The primary objective of the study is to determine whether once-daily rimegepant is more effective than placebo in reducing monthly migraine days relative to the observation period in adults with chronic migraine. Secondary objectives include evaluating differences between rimegepant and placebo in migraine responder rates, headache severity, acute migraine medication use, quality of life, work productivity, cognitive functioning, and safety and tolerability. Approximately 400 adults aged 18 years or older with a diagnosis of chronic migraine for at least 1 year will be enrolled at multiple study sites.
Conditions
- Preventive Treatment of Migraine
Interventions
RimegepantDrug
Rimegepant 75 mg orally disintegrating tablet (ODT) administered once daily during the 12-week double-blind treatment phase. Participants who enter the 12-week open-label extension phase will receive open-label rimegepant 75 mg once daily. During the open-label extension phase, participants may also take an additional dose of rimegepant 75 mg for the acute treatment of breakthrough headache attacks, up to 10 doses per month.
PlaceboDrug
Matching placebo orally disintegrating tablet administered once daily during the 12-week double-blind treatment phase. Participants who enter the 12-week open-label extension phase will receive open-label rimegepant 75 mg once daily. During the open-label extension phase, participants may also take an additional dose of rimegepant 75 mg for the acute treatment of breakthrough headache attacks, up to 10 doses per month.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Observation Phase in Monthly Migraine Days (MMDs) Over the Entire Double-Blind Treatment PhaseTime frame: 12 Weeks
Locations
38 sites in 4 countries. Site status is shown where the registry gives one.
Clinical Endpoints
Scottsdale, Arizona · Recruiting
Hope Clinical Research
Canoga Park, California · Recruiting
Neuro-Pain Research Center
Fresno, California · Recruiting
Clinical Research Institute
Los Angeles, California · Recruiting
Neurology Offices of South Florida PLLC
Boca Raton, Florida · Recruiting
Brainstorm Research Inc.
Miami, Florida · Recruiting
Conquest Research-Winter Park
Winter Park, Florida · Recruiting
Conquest Research, LLC
Atlanta, Georgia · Not yet recruiting
Josephson Wallack Munshower Neurology,PC
Indianapolis, Indiana · Recruiting
Collective Medical Research
Overland Park, Kansas · Recruiting
New England Regional Headache Center, Inc.
Worcester, Massachusetts · Recruiting
Michigan Headache & Neurological Institute
Ann Arbor, Michigan · Recruiting
StudyMetrix Research
City of Saint Peters, Missouri · Recruiting
Papillion Research Center / Avacare
Papillion, Nebraska · Recruiting
Dent Neurosciences Research Center, Inc
Amherst, New York · Not yet recruiting
Upstate Clinical Research Associates, LLC
Williamsville, New York · Recruiting
Hightower Clinical
Oklahoma City, Oklahoma · Recruiting
Clinical Neuroscience Solutions, LLC.
Memphis, Tennessee · Recruiting
FutureSearch Trials of Neurology
Austin, Texas · Recruiting
Austin Clinical Trial Partners
Austin, Texas · Recruiting
FutureSearch Trials of Dallas
Dallas, Texas · Recruiting
Highland Clinical Research
Salt Lake City, Utah · Not yet recruiting
Peking University People's Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Guangzhou First People's Hospital
Guangzhou, Guangdong, China · Not yet recruiting
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China · Not yet recruiting
Shaanxi Provincial People's Hospital
Xi'an, Shaanxi, China · Not yet recruiting
Xianyang Hospital of Yan'an University
Xianyang, Shaanxi, China · Not yet recruiting
First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China · Not yet recruiting
Hillel Yaffe Medical Center
Hadera, Israel · Recruiting
Sourasky Medical Center
Tel Aviv, Israel · Recruiting
Rabin Medical Center
Petah Tikva, Central District, Israel · Not yet recruiting
Sheba Medical Center
Ramat Gan, Central District, Israel · Not yet recruiting
Shaare Zedek Medical Center
Jerusalem, Jerusalem, Israel · Recruiting
St Pancras Clinical Research - London
London, United Kingdom · Recruiting
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom · Recruiting
Re:Cognition Health - London
London, United Kingdom · Not yet recruiting
University Hospitals Sussex NHS Foundation Trust
Brighton, EAST Sussex, United Kingdom · Not yet recruiting
Hull University Teaching Hospitals NHS Trust
Hull, EAST Yorkshire, United Kingdom · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.